Sprandel U, Zöllner N
Res Exp Med (Berl). 1985;185(1):77-85. doi: 10.1007/BF01851531.
Erythrocytes have been proposed as biogradable cellular carriers for drugs. Potentials of this therapeutic approach are organ-specific targeting, protection and prolonged in vivo function of the encapsulated drugs. Previous studies demonstrated the advantage of a hypo-osmotic dialysis procedure for macromolecule loading resulting in cells that are closely similar to normal erythrocytes. Osmotic fragility of unloaded and loaded "carrier" erythrocytes was studied both in respect of shelf-life and in vivo survival. Sudden haemolysis which is characteristic for normal erythrocytes was never obtained with carrier erythrocytes. Haemolysis appeared at all osmotic pressures and increased stepwise indicating the existence of various cell populations. However, the majority of cells were haemolysed at lower values of the osmotic fragility curve. Osmotic fragility was highly increased when cytotoxic chemotherapeutics were encapsulated, and these cells appeared as spherocytes using scanning electron microscopy. Osmotic fragility proved to be a simple but reliable method for the in vitro evaluation of carrier erythrocytes and the effect of the encapsulated substances.
红细胞已被提议作为药物的可生物降解细胞载体。这种治疗方法的潜力在于器官特异性靶向、对封装药物的保护以及延长其体内功能。先前的研究证明了低渗透析程序在大分子负载方面的优势,该程序可产生与正常红细胞极为相似的细胞。研究了未负载和负载“载体”红细胞在保质期和体内存活方面的渗透脆性。载体红细胞从未出现正常红细胞特有的突然溶血现象。在所有渗透压下均出现溶血,且呈逐步增加趋势,表明存在不同的细胞群体。然而,大多数细胞在渗透脆性曲线较低值时发生溶血。当封装细胞毒性化疗药物时,渗透脆性显著增加,使用扫描电子显微镜观察这些细胞呈球形红细胞。渗透脆性被证明是一种用于体外评估载体红细胞和封装物质效果的简单而可靠的方法。